IonQ buys UK quantum startup Oxford Ionics for more than $1 billion
IonQ is buying United Kingdom-based quantum computing startup Oxford Ionics in a deal valued at nearly $1.1 billion.
Shares gained about 4%.
The companies said in a release that the deal will combine IonQ's quantum computing hardware and software knowledge with Oxford Ionics' semiconductor chip technologies. The company aims to deliver breakthroughs in the field and capitalize on growing revenue opportunities.
"We believe the advantages of our combined technologies will set a new standard within quantum computing and deliver superior value for our customers through market-leading enterprise applications," said IonQ CEO Niccolo De Masi in a release.
The deal, which is expected to close this year, includes $1.065 billion worth of IonQ shares and about $10 million in cash. The merged company expects to build systems with 256 qubits by 2026, over 10,000 by 2027 and 2 million by 2030.
Interest in quantum computing has skyrocketed in recent months after technology giants Microsoft and Alphabet announced new chip breakthroughs. Experts tout the technology's ability to solve intricate computing tasks unachievable by other computers.
IonQ's CEO previously told CNBC that he wants the company to become the "800-pound gorilla" in the quantum world.
Shares of Maryland-based company, which went public through a special purpose acquisition company in late 2021, are down about 6% year to date. The stock has soared more than 400% from a year ago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Air Force spends millions on relaxation cubes that may prove worth it
At dozens of bases across the Air Force, troops are undertaking tried-and-true relaxation techniques — biofeedback, meditation — in shiny mirrored cubes that can project light patterns and even galaxies. The experience, as one researcher put it, is more like a 'Disney ride' than a studio or clinical office. This is Lumena Mindgym, a flashy new curriculum-based therapeutic tool that's taking the Air Force by storm. More than two dozens Mindgyms have been installed at base fitness centers and support facilities for about $100,000 apiece; Mindgym just marked its first installations outside the continental United States, in Kuwait and Turkey, earlier this year. As the number of Mindgym advocates across the Air Force grows, other services are also entering talks to purchase the technology. It's a lot of flash and glitz to deliver relaxation to stressed-out service members. But the number of passionate advocates for Mindgym in the military is growing, and some argue the attention it's getting from troops who might otherwise avoid meditation and de-stressing techniques might make it worth every penny. The technology itself was created by an entrepreneur with a finance background, rather than a scientist; company executives make clear they are not the clinical experts. 'We don't have anybody in-house that's a neuroscientist or Ph.D.,' Brandon Murphy, head of growth for Lumena, told Military Times in an interview, adding that they did maintain an advisory board of doctors and researchers. Nor was Mindgym designed with the military specifically in mind. Founders were shopping the technology at a Colorado-based sporting tradeshow in 2019, Murphy said, when they encountered Adam Strang, Biotechnology Product Line Lead at the Air Force Research Laboratory. Strang was intrigued by the tech and connected the team with veteran Air Force pilot and human performance expert Jannell MacAulay, who'd become a vocal advocate for Mindgym and help develop the curriculum to be used by airmen. 'It's like a flight simulator for your mind,' MacAulay posted on Facebook in April during a visit to one of the Air Force's facilities. By 2022, a seed fund grant had enabled the installation of the first Mindgym at Hill Air Force Base, Utah, complete with a clinically validated curriculum and wearable components that measured brain activity and heart rate. The first users were explosive ordnance disposal technicians from Hill's 775th Civil Engineering Squadron. And that initial group of 55 airmen gave Mindgym its best evidence for effectiveness. Over 219 20-minute training sessions, according to Lumena Labs, the group self-reported an average 30% improvement in mood. The biodata receptors documented a 16.2% reduction in stress indicators, while 61% of users said their stress management capabilities improved. Sleep quality also improved for 15% of users. 'Many in the group reported stronger focus during the Weighted Airmen Performance Systems (WAPS) testing — the program that determines promotions for Staff Sergeant (E-5) and Technical Sergeant (E-6),' Lumena stated in study analysis. 'They also cited decreased incidents of road rage and across-the-board improvements in their marital relations, gym workouts, and even their golf scores.' While follow-up studies have not been conducted, the feedback appears to demonstrate how even a small amount of therapeutic attention to the brain and the mental resilience of service members under stress can make a significant difference. Strang, at the Air Force Research Lab, told Military Times in an interview that Mindgym compared favorably to the sensory deprivation float tanks popular for promoting relaxation and stress reduction. 'Float tanks are messy and maintenance is challenging,' Strang said, adding that it was never clear to him if the atmosphere of the tank or the opportunity to take a nap in it made the most difference to his mental state. 'I hopped into Mindgym, and it didn't feel like a waterless float tank to me at all,' he said. 'It felt like a psychedelic experience.' AFRL has plans to study the efficacy of Mindgym in comparison with other mindfulness and relaxation technologies, though those are predicated on future funding awards. Strang emphasized that Mindgym is not a panacea for mental health or resilience but said boosting cognition and reducing stress, particularly in a 'next frontier' warfare environment where troops are joining a real fight from their desks as drone pilots or Space Force satellite operators, was worth the dedicated investment. 'They're $100,000 cubes, I think, the last time I checked,' Strang said. 'Let's say they facilitate relaxation and recovery across 100 people by 10%; what's the operational impact of that? I don't know. But what happens if one person who is flying an F-35 sits in that cockpit and, because of these interventions, prevents a mishap of a $60 million aircraft? Would that be worth it? Probably.' As the Air Force continues to install Mindgyms, the company has recently had more conversations with Navy officials, even demonstrating the Mindgym at the Sea Air Space naval trade show earlier this year. Murphy said he saw value for the technology particularly in the submarine community, where stress and operational tempo were high. There are now 32 different sessions a service member can select in Mindgym; a grant last year enabled the recent development and deployment of a stroboscopic light therapy protocol that is supposed to promote higher theta brain wave state, enabling reduced stress in high-intensity situations. 'I'd honestly love to have [a Mindgym] on every military base on the globe,' Murphy said, 'so that there's not a service member that doesn't have access to something like this.'
Yahoo
38 minutes ago
- Yahoo
IonQ Stock Unveils UK Oxford Ionics Acquisition, Nvidia Quantum Collaboration
IonQ (IONQ) announced the acquisition of a UK rival Monday and unveiled results of a collaboration involving semiconductor titan Nvidia (NVDA). IonQ said Monday it reached a deal to acquire UK quantum computing firm Oxford Ionics in a $1.08 billion primarily stock deal. The move 'accelerates our mission to full fault-tolerant quantum computers with 2 million physical qubits and 80,000 logical qubits by 2030,' IonQ CEO Niccolo de Masi said. Qubits are a measure of quantum computing power. IonQ stock rose 3% in recent trading. The shares are down about 4% in 2025 so far. Elsewhere in the sector, Quantum Computing (QUBT) added 7%, Rigetti (RGTI) shares were up 2%, and D-Wave Quantum (QBTS) stock slid 1%. Meanwhile, IonQ reported on its collaboration with Nvidia, Amazon (AMZN) Web Services, and pharmaceutical giant AstraZeneca (AZN) on the use of quantum computing in small molecule drug development. It said the project, which demonstrated a large-scale simulation of a chemical reaction used in the synthesis of pharmaceutical drugs, delivered a solution 20 times faster than previous benchmarks. IonQ said it will present further results this week at the ISC High Performance conference in Hamburg, Germany. Last month, IonQ shares rocketed higher after CEO Niccolo de Masi said aims to become the Nvidia of quantum computing. IonQ is 'in the business of quantum just like Nvidia and Broadcom are in the business of classical GPUs,' de Masi said in an interview with Barron's. 'I believe IonQ will be the Nvidia player." Read the original article on Investopedia
Yahoo
42 minutes ago
- Yahoo
Hologic Climbs 13% in a Month: How Should You Play the Stock?
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively. The current price is now 23.9% above the 52-week low of $51.90, boosted in part by reports that Hologic declined a private takeover bid from TPG and Blackstone. HOLX has also managed to outperform two of its key competitors — Exact Sciences EXAS and Becton, Dickinson and Company BDX, or BD, in the same time frame. Image Source: Zacks Investment Research Investor sentiment was already subdued after the release of the company's fiscal 2025 second-quarter earnings in early May. Hologic met adjusted EPS expectations with a modest revenue beat but revised its annual outlook due to the growing tariff impact from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market. In contrast, Exact Sciences anticipates 'little to no tariff impact' due to all domestic operations, while BD expects $90 million in tariff expenses for fiscal 2025, mostly from China imports. That said, let's explore what might be driving Hologic's recent rally. On May 27, HOLX shares rose nearly 15% following a report from the Financial Times that the company turned down a non-binding offer from private equity (PE) firms TPG and Blackstone. The deal was valued at up to $16.7 billion, including debt. These firms, known for their solid history of healthcare investments, teamed up last year to explore a potential acquisition of Bausch + Lomb, which eventually did not happen. The proposed takeover bid of Hologic would have been one of the largest leveraged buyouts of the year, valuing the company's shares between $70 and $72 — roughly a 30% premium to the May 23 closing price of $54.28. The report also stated that there is a possibility the deal discussions might resume, according to people with knowledge of the matter. Hologic has attracted buyers' attention for a while now. Of late, the take-private activities by PE firms have seen a sharp increase, such as Sycamore Partners' $24 billion deal for Walgreens Boots Alliance, Thoma Bravo's $10.6 billion acquisition of Boeing's software unit, and 3G Capital's $10.5 billion deal for Skechers. Nonetheless, the high premium in the offer signals strong confidence in Hologic's growth potential. The company presented new data showing the significant clinical impact of the Breast Cancer Index ('BCI') test at the 2025 American Society of Clinical Oncology Annual Meeting held on June 2. The molecular, gene expression-based test from Hologic's subsidiary, Biotheranostics, has been a key growth driver in the molecular diagnostics business over the past few quarters. The latest data from the prospective, multi-center BCI Registry Study highlights how this genomic test plays a critical role in guiding extended endocrine therapy decisions for women with early-stage, hormone receptor-positive (HR+) breast cancer. With more than 2,800 patients involved, the study found that BCI testing led to a change in treatment recommendations for about four in 10 cases. Additionally, physicians' confidence in their treatment recommendations got a boost, while patients felt comfortable in their decisions, citing fewer concerns about cost, drug safety and preference related to extended endocrine therapy benefits. Hologic looks attractive from a valuation standpoint. The stock has been trading at a price-to-sales (P/S) of 3.40X over the past five years compared to its median of 4.33X and the industry average of 4.16X. It has a Value Score of B at present. Image Source: Zacks Investment Research Meanwhile, both Exact Sciences and BD are trading at a premium to their industry average, with P/S of 3.16X and 2.20X respectively. Molecular Diagnostics assays are likely to continue to be the principal revenue-generating component in the Diagnostics division. As Hologic drives awareness and reimbursement in the highly unpenetrated U.S. vaginitis market, the BV CV/TV assay is poised to see a strong uptake. Aligning with its long-term revenue diversification strategy, the company's Breast Health service revenues are now larger and growing more steadily than the gantry business. The 2024 acquisition of Endomagnetics boosted the Interventional Breast portfolio with market-leading product lines and strong R&D capabilities for further portfolio expansion. The upcoming launch of innovations like the Envision Mammography Platform is likely to gain a favorable reception. In Surgical, Myosure's strong international growth points to the high demand for minimally invasive options for treating uterine polyps and fibroids. Hologic continues to expand this division both organically and through acquisitions such as Gynsesonics, leveraging its established sales channel. Further, the company is building capabilities to grow internationally on a consistent basis by going directly into more geographies and businesses. A consistently strong profitability has contributed to a fortress balance sheet over time, allowing Hologic to execute on both tuck-in M&A and share repurchases. Based on short-term price targets offered by 15 analysts, the Zacks average price target is $68.13 per share. The average suggests a potential 8.02% upside from last Friday's closing price. Image Source: Zacks Investment Research Hologic has some promising catalysts for long-term expansion, supported by an attractive valuation relative to its industry. However, despite outperforming peers over the past month, the Zacks Rank #3 (Hold) stock is navigating a turbulent macroeconomic landscape, which is expected to weigh on its financial performance in the near term. Hence, those eyeing HOLX may find it wise to wait for a better entry point, while current shareholders should retain their position. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
